Successful	B:C0376636
Management	I:C0376636
of	O
Acquired	O
Hemophilia	O
A	I:C0019069
Associated	O
with	O
Bullous	O
Pemphigoid	I:C0030805
:	O
A	O
Case	O
Report	I:C0085973
and	O
Review	O
of	I:C0282441
the	I:C0282441
Literature	I:C0282441
.	O

Successful	O
Management	I:C0376636
of	O
Acquired	O
Hemophilia	B:C0019069
A	I:C0019069
Associated	O
with	O
Bullous	O
Pemphigoid	I:C0030805
:	O
A	O
Case	O
Report	I:C0085973
and	O
Review	O
of	I:C0282441
the	I:C0282441
Literature	I:C0282441
.	O

Successful	O
Management	I:C0376636
of	O
Acquired	O
Hemophilia	O
A	I:C0019069
Associated	O
with	O
Bullous	B:C0030805
Pemphigoid	I:C0030805
:	O
A	O
Case	O
Report	I:C0085973
and	O
Review	O
of	I:C0282441
the	I:C0282441
Literature	I:C0282441
.	O

Successful	O
Management	I:C0376636
of	O
Acquired	O
Hemophilia	O
A	I:C0019069
Associated	O
with	O
Bullous	O
Pemphigoid	I:C0030805
:	O
A	O
Case	B:C0085973
Report	I:C0085973
and	O
Review	O
of	I:C0282441
the	I:C0282441
Literature	I:C0282441
.	O

Successful	O
Management	I:C0376636
of	O
Acquired	O
Hemophilia	O
A	I:C0019069
Associated	O
with	O
Bullous	O
Pemphigoid	I:C0030805
:	O
A	O
Case	O
Report	I:C0085973
and	O
Review	B:C0282441
of	I:C0282441
the	I:C0282441
Literature	I:C0282441
.	O

Acquired	O
hemophilia	B:C0019069
A	I:C0019069
(	O
Acquired	O
hemophilia	I:C0019069
A	I:C0019069
)	O
is	O
a	O
rare	O
condition	I:C0678236
,	O
due	O
to	O
the	O
spontaneous	O
formation	O
of	O
neutralizing	O
antibodies	I:C0475463
against	O
endogenous	O
factor	O
VIII	O
.	O

Acquired	O
hemophilia	O
A	I:C0019069
(	O
Acquired	B:C0019069
hemophilia	I:C0019069
A	I:C0019069
)	O
is	O
a	O
rare	O
condition	I:C0678236
,	O
due	O
to	O
the	O
spontaneous	O
formation	O
of	O
neutralizing	O
antibodies	I:C0475463
against	O
endogenous	O
factor	O
VIII	O
.	O

Acquired	O
hemophilia	O
A	I:C0019069
(	O
Acquired	O
hemophilia	I:C0019069
A	I:C0019069
)	O
is	O
a	O
rare	B:C0678236
condition	I:C0678236
,	O
due	O
to	O
the	O
spontaneous	O
formation	O
of	O
neutralizing	O
antibodies	I:C0475463
against	O
endogenous	O
factor	O
VIII	O
.	O

Acquired	O
hemophilia	O
A	I:C0019069
(	O
Acquired	O
hemophilia	I:C0019069
A	I:C0019069
)	O
is	O
a	O
rare	O
condition	I:C0678236
,	O
due	O
to	O
the	O
spontaneous	O
formation	O
of	O
neutralizing	B:C0475463
antibodies	I:C0475463
against	O
endogenous	O
factor	O
VIII	O
.	O

About	O
half	O
the	O
cases	O
are	O
associated	O
with	O
pregnancy	B:C0032961
,	O
postpartum	O
,	O
autoimmune	O
diseases	I:C0004364
,	O
malignancies	O
,	O
or	O
adverse	O
drug	I:C0041755
reactions	I:C0041755
.	O

About	O
half	O
the	O
cases	O
are	O
associated	O
with	O
pregnancy	O
,	O
postpartum	O
,	O
autoimmune	B:C0004364
diseases	I:C0004364
,	O
malignancies	O
,	O
or	O
adverse	O
drug	I:C0041755
reactions	I:C0041755
.	O

About	O
half	O
the	O
cases	O
are	O
associated	O
with	O
pregnancy	O
,	O
postpartum	O
,	O
autoimmune	O
diseases	I:C0004364
,	O
malignancies	B:C4282132
,	O
or	O
adverse	O
drug	I:C0041755
reactions	I:C0041755
.	O

About	O
half	O
the	O
cases	O
are	O
associated	O
with	O
pregnancy	O
,	O
postpartum	O
,	O
autoimmune	O
diseases	I:C0004364
,	O
malignancies	O
,	O
or	O
adverse	B:C0041755
drug	I:C0041755
reactions	I:C0041755
.	O

Symptoms	B:C1457887
include	O
severe	O
and	O
unexpected	O
bleeding	O
that	O
may	O
prove	O
life	O
-	I:C2826244
threatening	I:C2826244
.	O

Symptoms	O
include	O
severe	O
and	O
unexpected	O
bleeding	B:C0019080
that	O
may	O
prove	O
life	O
-	I:C2826244
threatening	I:C2826244
.	O

Symptoms	O
include	O
severe	O
and	O
unexpected	O
bleeding	O
that	O
may	O
prove	O
life	B:C2826244
-	I:C2826244
threatening	I:C2826244
.	O

Case	B:C0085973
Study	I:C0085973
.	O

We	O
report	B:C0684224
a	O
case	O
of	O
Acquired	O
hemophilia	I:C0019069
A	I:C0019069
associated	O
with	O
bullous	O
pemphigoid	I:C0030805
(	O
bullous	O
pemphigoid	I:C0030805
)	O
,	O
a	O
chronic	O
,	O
autoimmune	O
,	O
subepidermal	O
,	O
blistering	O
skin	I:C4314154
disease	I:C4314154
.	O

We	O
report	O
a	O
case	O
of	O
Acquired	B:C0019069
hemophilia	I:C0019069
A	I:C0019069
associated	O
with	O
bullous	O
pemphigoid	I:C0030805
(	O
bullous	O
pemphigoid	I:C0030805
)	O
,	O
a	O
chronic	O
,	O
autoimmune	O
,	O
subepidermal	O
,	O
blistering	O
skin	I:C4314154
disease	I:C4314154
.	O

We	O
report	O
a	O
case	O
of	O
Acquired	O
hemophilia	I:C0019069
A	I:C0019069
associated	O
with	O
bullous	B:C0030805
pemphigoid	I:C0030805
(	O
bullous	O
pemphigoid	I:C0030805
)	O
,	O
a	O
chronic	O
,	O
autoimmune	O
,	O
subepidermal	O
,	O
blistering	O
skin	I:C4314154
disease	I:C4314154
.	O

We	O
report	O
a	O
case	O
of	O
Acquired	O
hemophilia	I:C0019069
A	I:C0019069
associated	O
with	O
bullous	O
pemphigoid	I:C0030805
(	O
bullous	B:C0030805
pemphigoid	I:C0030805
)	O
,	O
a	O
chronic	O
,	O
autoimmune	O
,	O
subepidermal	O
,	O
blistering	O
skin	I:C4314154
disease	I:C4314154
.	O

We	O
report	O
a	O
case	O
of	O
Acquired	O
hemophilia	I:C0019069
A	I:C0019069
associated	O
with	O
bullous	O
pemphigoid	I:C0030805
(	O
bullous	O
pemphigoid	I:C0030805
)	O
,	O
a	O
chronic	O
,	O
autoimmune	B:C0004368
,	O
subepidermal	O
,	O
blistering	O
skin	I:C4314154
disease	I:C4314154
.	O

We	O
report	O
a	O
case	O
of	O
Acquired	O
hemophilia	I:C0019069
A	I:C0019069
associated	O
with	O
bullous	O
pemphigoid	I:C0030805
(	O
bullous	O
pemphigoid	I:C0030805
)	O
,	O
a	O
chronic	O
,	O
autoimmune	O
,	O
subepidermal	B:C1856956
,	O
blistering	O
skin	I:C4314154
disease	I:C4314154
.	O

We	O
report	O
a	O
case	O
of	O
Acquired	O
hemophilia	I:C0019069
A	I:C0019069
associated	O
with	O
bullous	O
pemphigoid	I:C0030805
(	O
bullous	O
pemphigoid	I:C0030805
)	O
,	O
a	O
chronic	O
,	O
autoimmune	O
,	O
subepidermal	O
,	O
blistering	B:C4314154
skin	I:C4314154
disease	I:C4314154
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
25th	O
documented	B:C1301725
case	O
of	O
such	O
an	O
association	O
.	O

Following	O
treatment	B:C0087111
for	O
less	O
than	O
3	O
months	O
consisting	O
of	O
methylprednisolone	O
at	O
decreasing	O
dose	O
levels	O
along	O
with	O
four	O
courses	O
of	O
rituximab	O
(	O
monoclonal	O
antibody	I:C0003250
directed	O
against	O
the	O
CD20	O
protein	I:C1447954
)	O
,	O
Acquired	O
hemophilia	I:C0019069
A	I:C0019069
was	O
completely	O
cured	O
and	O
bullous	O
pemphigoid	I:C0030805
well	O
-	O
controlled	O
.	O

Following	O
treatment	O
for	O
less	O
than	O
3	O
months	O
consisting	O
of	O
methylprednisolone	B:C0025815
at	O
decreasing	O
dose	O
levels	O
along	O
with	O
four	O
courses	O
of	O
rituximab	O
(	O
monoclonal	O
antibody	I:C0003250
directed	O
against	O
the	O
CD20	O
protein	I:C1447954
)	O
,	O
Acquired	O
hemophilia	I:C0019069
A	I:C0019069
was	O
completely	O
cured	O
and	O
bullous	O
pemphigoid	I:C0030805
well	O
-	O
controlled	O
.	O

Following	O
treatment	O
for	O
less	O
than	O
3	O
months	O
consisting	O
of	O
methylprednisolone	O
at	O
decreasing	B:C0442797
dose	O
levels	O
along	O
with	O
four	O
courses	O
of	O
rituximab	O
(	O
monoclonal	O
antibody	I:C0003250
directed	O
against	O
the	O
CD20	O
protein	I:C1447954
)	O
,	O
Acquired	O
hemophilia	I:C0019069
A	I:C0019069
was	O
completely	O
cured	O
and	O
bullous	O
pemphigoid	I:C0030805
well	O
-	O
controlled	O
.	O

Following	O
treatment	O
for	O
less	O
than	O
3	O
months	O
consisting	O
of	O
methylprednisolone	O
at	O
decreasing	O
dose	O
levels	O
along	O
with	O
four	O
courses	O
of	O
rituximab	B:C0393022
(	O
monoclonal	O
antibody	I:C0003250
directed	O
against	O
the	O
CD20	O
protein	I:C1447954
)	O
,	O
Acquired	O
hemophilia	I:C0019069
A	I:C0019069
was	O
completely	O
cured	O
and	O
bullous	O
pemphigoid	I:C0030805
well	O
-	O
controlled	O
.	O

Following	O
treatment	O
for	O
less	O
than	O
3	O
months	O
consisting	O
of	O
methylprednisolone	O
at	O
decreasing	O
dose	O
levels	O
along	O
with	O
four	O
courses	O
of	O
rituximab	O
(	O
monoclonal	B:C0003250
antibody	I:C0003250
directed	O
against	O
the	O
CD20	O
protein	I:C1447954
)	O
,	O
Acquired	O
hemophilia	I:C0019069
A	I:C0019069
was	O
completely	O
cured	O
and	O
bullous	O
pemphigoid	I:C0030805
well	O
-	O
controlled	O
.	O

Following	O
treatment	O
for	O
less	O
than	O
3	O
months	O
consisting	O
of	O
methylprednisolone	O
at	O
decreasing	O
dose	O
levels	O
along	O
with	O
four	O
courses	O
of	O
rituximab	O
(	O
monoclonal	O
antibody	I:C0003250
directed	O
against	O
the	O
CD20	B:C1447954
protein	I:C1447954
)	O
,	O
Acquired	O
hemophilia	I:C0019069
A	I:C0019069
was	O
completely	O
cured	O
and	O
bullous	O
pemphigoid	I:C0030805
well	O
-	O
controlled	O
.	O

Following	O
treatment	O
for	O
less	O
than	O
3	O
months	O
consisting	O
of	O
methylprednisolone	O
at	O
decreasing	O
dose	O
levels	O
along	O
with	O
four	O
courses	O
of	O
rituximab	O
(	O
monoclonal	O
antibody	I:C0003250
directed	O
against	O
the	O
CD20	O
protein	I:C1447954
)	O
,	O
Acquired	B:C0019069
hemophilia	I:C0019069
A	I:C0019069
was	O
completely	O
cured	O
and	O
bullous	O
pemphigoid	I:C0030805
well	O
-	O
controlled	O
.	O

Following	O
treatment	O
for	O
less	O
than	O
3	O
months	O
consisting	O
of	O
methylprednisolone	O
at	O
decreasing	O
dose	O
levels	O
along	O
with	O
four	O
courses	O
of	O
rituximab	O
(	O
monoclonal	O
antibody	I:C0003250
directed	O
against	O
the	O
CD20	O
protein	I:C1447954
)	O
,	O
Acquired	O
hemophilia	I:C0019069
A	I:C0019069
was	O
completely	O
cured	O
and	O
bullous	B:C0030805
pemphigoid	I:C0030805
well	O
-	O
controlled	O
.	O

This	O
report	B:C0684224
illustrates	O
a	O
rare	O
association	O
of	O
Acquired	O
hemophilia	I:C0019069
A	I:C0019069
and	O
bullous	O
pemphigoid	I:C0030805
,	O
supporting	O
the	O
possibility	O
of	O
eradicating	O
the	O
inhibitor	O
with	O
a	O
well	O
-	O
conducted	O
short	O
-	O
term	O
treatment	O
.	O

This	O
report	O
illustrates	O
a	O
rare	O
association	O
of	O
Acquired	B:C0019069
hemophilia	I:C0019069
A	I:C0019069
and	O
bullous	O
pemphigoid	I:C0030805
,	O
supporting	O
the	O
possibility	O
of	O
eradicating	O
the	O
inhibitor	O
with	O
a	O
well	O
-	O
conducted	O
short	O
-	O
term	O
treatment	O
.	O

This	O
report	O
illustrates	O
a	O
rare	O
association	O
of	O
Acquired	O
hemophilia	I:C0019069
A	I:C0019069
and	O
bullous	B:C0030805
pemphigoid	I:C0030805
,	O
supporting	O
the	O
possibility	O
of	O
eradicating	O
the	O
inhibitor	O
with	O
a	O
well	O
-	O
conducted	O
short	O
-	O
term	O
treatment	O
.	O

This	O
report	O
illustrates	O
a	O
rare	O
association	O
of	O
Acquired	O
hemophilia	I:C0019069
A	I:C0019069
and	O
bullous	O
pemphigoid	I:C0030805
,	O
supporting	O
the	O
possibility	O
of	O
eradicating	B:C3178994
the	O
inhibitor	O
with	O
a	O
well	O
-	O
conducted	O
short	O
-	O
term	O
treatment	O
.	O

This	O
report	O
illustrates	O
a	O
rare	O
association	O
of	O
Acquired	O
hemophilia	I:C0019069
A	I:C0019069
and	O
bullous	O
pemphigoid	I:C0030805
,	O
supporting	O
the	O
possibility	O
of	O
eradicating	O
the	O
inhibitor	O
with	O
a	O
well	O
-	O
conducted	O
short	O
-	O
term	O
treatment	B:C0087111
.	O

